Type 2 Diabetes

Explore the urgent need for diabetes specialists and the American College of Diabetology's efforts to enhance care through education and certification.

Hosts sit down for a deep dive into The Diabetes Collective and what it's like operating a diabetes clinic in the modern healthcare landscape.

A recent cross-sectional analysis has estimated the size of the American population with both MASLD and T2DM eligible for treatment.

Verma went over the STRIDE trial evaluating the GLP-1 RA and its latest findings presented at ADA Scientific Sessions.

Li and Shao discussed the heavy disease burden of type 2 diabetes in the VA population and outlined the VA MOVE! study.

Discover how the CATALYST trial reveals mifepristone's potential to enhance glycemic control and weight loss in challenging type 2 diabetes cases.

Mifepristone shows promise in improving glycemic control and reducing weight in patients with hypercortisolism and type 2 diabetes.

Maridebart cafraglutide shows potential as a monthly treatment for obesity and type 2 diabetes, demonstrating significant weight loss and glycemic improvements.

Sandforth emphasized the important of achieving prediabetes remission for preventing T2D as seen in his new research.

Explore groundbreaking findings from the REDEFINE trials on CagriSema's impact on weight loss and diabetes management at ADA 2025.

Philis-Tsimikas shared the latest findings demonstrating inferiority after switching from daily basal insulin to weekly insulin efsitora.

Kevin Sayer joins the program to discuss the latest from Dexcom and preview where the business is headed in an evolving diabetes landscape.

A new study reveals once-weekly efsitora alfa effectively lowers blood glucose in type 2 diabetes.

Steger discussed findings from a 6-month lifestyle investigating TRE+ER and IER.

A global study reveals that universal access to semaglutide could save 28 million lives and significantly reduce obesity and diabetes worldwide.

CagriSema shows weight loss results in recent trials comparable to existing interventions.

Xue discussed her research developing a personalized prediction algorithm for predicting responders to a DPP-style intervention.

New findings reveal semaglutide significantly enhances walking ability and quality of life for patients with T2D and PAD.

The ACHIEVE-1 trial reveals orforglipron's potential as a breakthrough treatment for type 2 diabetes.

An overview of 7 presentations included as late-breaking clinical trials at ADA 2025.

In this special episode, cohosts preview the most anticipated data and explore clinical implications in diabetes and obesity.

Budoff suggests monitoring serum lipoproteins like Lp(a) and ApoB to predict cardiovascular disease risk in patients with no conventional indicators.

Lopez discusses the evolving understanding of the utility of SGLT2 inhibitors and GLP-1 RAs in heart failure care, including both HFpEF and HFrEF.

Incretin-based therapies for obesity and diabetes may be capable of treating a much wider range of diseases, including Alzheimer’s and Parkinson’s.

The pooled analysis of BROOKLYN and BROADWAY data outline obicetrapib’s impact on HbA1c reduction and a trend toward lower new-onset diabetes risk.